Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C, Kraeber-Bodéré F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, Campion L, Harousseau JL, Wegener WA, Goldenberg DM, Huglo D. Bodet-Milin C, et al. Among authors: morschhauser f. Haematologica. 2008 Mar;93(3):390-7. doi: 10.3324/haematol.10591. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268287 Free article. Clinical Trial.
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM. Morschhauser F, et al. J Clin Oncol. 2010 Aug 10;28(23):3709-16. doi: 10.1200/JCO.2009.27.7863. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625137 Clinical Trial.
Diversity in antibody-based approaches to non-Hodgkin lymphoma.
Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Maloney D, et al. Among authors: morschhauser f. Leuk Lymphoma. 2010 Aug;51 Suppl 1:20-7. doi: 10.3109/10428194.2010.500047. Leuk Lymphoma. 2010. PMID: 20815760 Review.
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquières H, Bouabdallah K, Morschhauser F, Coiffier B, Le Gouill S, Bologna S, Delarue R, Huynh A, Bosly A, Brière J, Gisselbrecht C. Decaudin D, et al. Among authors: morschhauser f. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212-8. doi: 10.1016/j.clml.2011.03.007. Epub 2011 Apr 9. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21575926 Clinical Trial.
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, Agarwal S, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Morschhauser F. Palomba ML, et al. Among authors: morschhauser f. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):504-512. doi: 10.1016/j.clml.2021.12.014. Epub 2021 Dec 24. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35151584 Free article. Clinical Trial.
Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant.
Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N; Groupe d'Etude des Lymphomes de l'Adulte. Heutte N, et al. Among authors: morschhauser f. Leuk Lymphoma. 2011 Jul;52(7):1239-48. doi: 10.3109/10428194.2011.566951. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463114 Clinical Trial.
326 results